Our Why

“We are leveraging our cutting-edge science to develop lifesaving and life altering therapies for patients with rare immunological diseases.”

Søren Tulstrup, President and CEO

Latest news

Nov 15, 2021

Hansa Biopharma to initiate Phase 3 study of imlifidase to treat anti-Glomerular Basement Membrane (anti-GBM) disease after successful pre-IND meeting with U.S. FDA

Nov 12, 2021

Hansa Biopharma Nomination Committee formed

Nov 08, 2021

Hansa Biopharma announces it has confidentially submitted a draft registration statement on Form F-1 to the U.S. SEC relating to a potential U.S. IPO

Stockholm
...
(...%)

HNSA ... SEK

Annual report 2020	EN	SE
Latest Financial Report	EN	SE

Events & Webcasts

16Nov

Jefferies Global Healthcare Conference

London/virtual

25Nov

Erik Penser Banks Bolagsdag

29Nov

ABG Rare Disease Day Stockholm

Stockholm/Virtual

Introduction to Hansa

Søren Tulstrup, President & CEO

Join Hansa

From our headquarters in Lund, Sweden, we reach around the world. Our dedicated team includes experienced and courageous specialists driven by our purpose to develop lifesaving and life altering therapies for patients living with rare immunological diseases.

Since our founding in 2007, we have worked in cross functional and agile teams. We are gender-balanced, representing a vast number of nationalities and see diversity as an enabler for reaching our corporate objectives. The recruitment of highly motivated, experienced and talented team players supports our development towards a fully integrated global biopharmaceutical company.

During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work^® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud.

Careers